Literature DB >> 24388224

AChR-myasthenia gravis switching to double-seropositive several years after the onset.

Vasiliki Zouvelou1, Paraskevi Zisimopoulou2, Erasmia Psimenou3, Eirini Matsigkou2, Eleftherios Stamboulis4, Socrates J Tzartos5.   

Abstract

We report an early onset AChR-myasthenia gravis (MG) with biphasic clinical course. The clinical "switch" from AChR-MG to MuSK-MG emerged 16 years after the onset and 11 years after thymectomy. MuSK antibodies were detected only by cell-based assay and only upon clinical "switch", while AChR antibodies remained positive and at high titers during the whole disease course. Although the occurrence of AChR antibodies and MuSK antibodies in the same individual is rare, the re-assessment of the antibody status, using all available assays, is advisable when there is clinical indication.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor; Biphasic course; Cell-based assay; Double seropositive; Muscle-specific kinase; Myasthenia gravis

Mesh:

Substances:

Year:  2013        PMID: 24388224     DOI: 10.1016/j.jneuroim.2013.12.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Predictors of outcome of myasthenic crisis.

Authors:  Nan Liu; Qi Liu; Xiujuan Wu; Kangding Liu; Quo Vadis
Journal:  Neurol Sci       Date:  2014-07-25       Impact factor: 3.307

3.  Is double-seropositive myasthenia gravis a distinct subtype?

Authors:  Vaibhav Seth; Suman Kushwaha; Prateek Bapat; KiranGowda Rajashekar; Deepti Grover
Journal:  Acta Neurol Belg       Date:  2021-07-26       Impact factor: 2.396

4.  Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis.

Authors:  Berit Jordan; Susanne Schilling; Stephan Zierz
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

5.  Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.

Authors:  Jianmeng Wang; Xiujuan Wu; Hui Deng; Ye Liu; Hongping Liu; Xueli Fan; Kangding Liu; Jiang Wu; Hong-Liang Zhang
Journal:  Neurosciences (Riyadh)       Date:  2016-01       Impact factor: 0.906

6.  Clinical application of clustered-AChR for the detection of SNMG.

Authors:  Guang Zhao; Xiaoqing Wang; Xiaowen Yu; Xiutian Zhang; Yangtai Guan; Jianming Jiang
Journal:  Sci Rep       Date:  2015-06-11       Impact factor: 4.379

7.  Comorbidities and Long-Term Outcomes in a Cohort with Myasthenic Crisis: Experiences from a Tertiary Care Center.

Authors:  Ajith Sivadasan; Mathew Alexander; Sanjith Aaron; Vivek Mathew; Shalini Nair; Karthik Muthusamy; A T Prabhakar; Rohit N Benjamin; Atif Shaikh; Gideon Rynjah
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.